Lidbury Brett A, Kita Badia, Lewis Donald P, Hayward Susan, Ludlow Helen, Hedger Mark P, de Kretser David M
Pattern Recognition and Pathology, Department of Genome Sciences, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT, 2601, Australia.
The National Centre for Epidemiology and Public Health, The Research School of Population Health, ANU, Canberra, ACT, 2601, Australia.
J Transl Med. 2017 Mar 16;15(1):60. doi: 10.1186/s12967-017-1161-4.
Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available.
A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin reference population were also performed. For the total study cohort the age range was 18-65 years with a female: male participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference intervals.
Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. All routine and special pathology markers were within the normal laboratory reference intervals for the total study cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma.
Elevated activin B levels together with normal activin A levels identified patients with the diagnostic symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and capture the diverse array of symptoms experienced by CFS/ME patients.
研究激活素家族蛋白作为慢性疲劳综合征/肌痛性脑脊髓炎(CFS/ME)的血清生物标志物。CFS/ME是一种症状复杂、范围广泛的疾病,其特征为持续6个月或更长时间的疲劳,尤其是在运动后。目前尚无明确的生物标志物。
对符合2003年加拿大共识标准的CFS/ME患者进行了一项横断面观察性研究,并与健康的非疲劳对照组进行了平行研究。还与先前定义的激活素参考人群进行了比较。整个研究队列的年龄范围为18至65岁,女性与男性参与者的比例大于3:1。所有参与者均通过初级保健社区诊所进行评估。在体格检查和直立不耐受评估后采集血样进行病理学检测。还对这些样本的血清中的细胞因子、激活素A、激活素B和卵泡抑素进行了测量。对CFS/ME组和对照组的所有数据进行了比较,激活素和卵泡抑素也与先前定义的参考区间进行了比较。
与研究对照组以及既定参考区间相比,CFS/ME参与者的血清激活素B水平显著升高。血清激活素A和卵泡抑素在正常范围内。整个研究队列的所有常规和特殊病理学标志物均在实验室正常参考区间内,CFS/ME组和对照组之间未检测到显著差异。此外,白细胞介素-2、白细胞介素-4、白细胞介素-6、白细胞介素-10、白细胞介素-17A、肿瘤坏死因子或干扰素-γ也未检测到显著差异。
激活素B水平升高而激活素A水平正常可识别出具有CFS/ME诊断症状的患者,从而提供了一种基于血清的新型检测方法。激活素具有多种生理作用,并能反映CFS/ME患者所经历的各种症状。